Monday, 11 September 2017

Regeneron, Sanofi asthma drug data fails to excite investors

PARIS (Reuters) - Shares of Regeneron Inc and Sanofi SA slid on Monday after late-stage trial data for their asthma drug, dupilumab, fell short of investor expectations.


No comments:

Post a Comment